Journal article

Antagonism of antiviral and allogeneic activity of a human public CTL clonotype by a single altered peptide ligand: Implications for allograft rejection

LK Ely, KJ Green, T Beddoe, CS Clements, JJ Miles, SP Bottomley, D Zernich, L Kjer-Nielsen, AW Purcell, J McCluskey, J Rossjohn, SR Burrows

JOURNAL OF IMMUNOLOGY | AMER ASSOC IMMUNOLOGISTS | Published : 2005

Abstract

Alloreactive T lymphocytes are central mediators of graft-versus-host disease and allograft rejection. A public CTL clonotype with specificity for the alloantigens HLA-B*4402 and B*4405 is often expanded to large numbers in healthy HLA-B*0801(+) individuals, driven by cross-reactive stimulation with the common, persistent herpesvirus EBV. Since such alloreactive memory CTL expansions have the potential to influence transplantation outcome, altered peptide ligands (APLs) of the target HLA-B*0801-binding EBV peptide, FLRGRAYGL, were screened as specific antagonists for this immunodominant clonotype. One APL, FLRGRFYGL, exerted powerful antagonism of a prototypic T cell clone expressing this im..

View full abstract

University of Melbourne Researchers